Advertisements

Rexahn Pharmaceuticals Inc. (RNN) Stock Quote

Detailed Quote for Rexahn Pharmaceuticals Inc. (RNN)
$ 2.29   0.02 (+0.88%) Volume: 68.09k 2:09 PM EDT Sep 20, 2017
Today 5d 1m 3m 1y more
Last Price
2.29
Change $
0.02
Change %
0.88%
Tick
  
Bid
2.28
Bid Size
1,000
Ask
2.31
Ask Size
500
Open
2.32
High
2.33
Low
2.26
Prev Close
2.27
Last Trade
2:09
Volume
68.09k
52 Wk Hi
7.0999999
52 Wk Low
1.26999998
Market Cap
65.17m
Ex-Div Date
N/A
Div Rate
N/A
Yield
N/A
Shares
28,459,805
EPS (TTM)
-0.970000028
PE Ratio
N/A
Exchange
NYSE American
News and Media for Rexahn Pharmaceuticals Inc. (RNN)
Sector News | Topic News
News for Rexahn Pharmaceuticals Inc. (RNN)
Mon, Sep 11, 2017
9:43 AM Rexahn Pharma updates on pipeline candidates Supinoxin and RX-3117; shares ahead 6% - SeekingAlpha
9:29 AM Premarket Gainers as of 9:05 am - SeekingAlpha
8:15 AM Rexahn Pharmaceuticals Presents Final Data from the Supinoxin(TM) Phase I Clinical study and New Preclinical Data on RX-3117 at the 2017 European Society for Medical Oncology (ESMO) Congress - GlobeNewswire
Sun, Sep 10, 2017
8:15 AM Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Advanced Bladder Cancer at the 2017 European Society for Medical Oncology (ESMO) Congress - GlobeNewswire
Wed, Sep 06, 2017
9:00 AM Rexahn Pharmaceuticals to Present at 19th Annual Rodman & Renshaw Global Investment Conference - GlobeNewswire
Tue, Sep 05, 2017
9:00 AM Rexahn Pharmaceuticals to Present Updated Clinical and Preclinical Data at the 2017 European Society for Medical Oncology (ESMO) Congress - GlobeNewswire
Fri, Sep 01, 2017
9:00 AM Rexahn Pharmaceuticals Announces Retirement of its Founder, Chang Ahn, Ph.D., from the Board of Directors - GlobeNewswire
Wed, Aug 30, 2017
9:00 AM Rexahn Pharmaceuticals Receives New U.S. Patent for Supinoxin(TM) - GlobeNewswire
8:00 AM Rexahn, Pipeline Updates, Q2 Financial Review, Analysts Target Price - ACCESSWIRE IA
8:00 AM Today's Research Reports on Trending Tickers: Rexahn Pharmaceuticals and Valeant Pharmaceuticals - ACCESSWIRE IA
Tue, Aug 29, 2017
12:43 PM Midday Gainers / Losers - SeekingAlpha
Mon, Aug 14, 2017
9:00 AM Rexahn Pharmaceuticals Issues Mid-Year Shareholder Letter to Review Recent Progress and Clinical Plans - GlobeNewswire
Mon, Aug 07, 2017
9:00 AM Rexahn Pharmaceuticals Reports Second Quarter 2017 Financial and Operational Results - GlobeNewswire
Mon, Jul 10, 2017
9:01 AM Rexahn Pharmaceuticals Receives Notice of Allowance for a New U.S. Patent Covering the Use of RX-3117 - GlobeNewswire
Wed, Jun 07, 2017
12:38 PM Midday Gainers / Losers - SeekingAlpha
11:36 AM Rexahn Pharma announces direct equity sale to institutional investors; shares slip 15% - SeekingAlpha
9:19 AM Premarket Losers as of 9:05 am - SeekingAlpha
8:50 AM Rexahn Announces $10 Million Registered Direct Offering - GlobeNewswire
Sun, Jun 04, 2017
9:00 AM Rexahn Pharmaceuticals Presents Preliminary Efficacy Data from the Ongoing Phase IIa Clinical Trial of RX-3117 in Metastatic Bladder Cancer at the American Society of Clinical Oncology (ASCO) 2017 Annual Meeting - GlobeNewswire
Tue, May 09, 2017
12:57 PM Midday Gainers / Losers - SeekingAlpha
More News for RNN >>

Tags for Rexahn Pharmaceuticals Inc.

Research stocks or mutual funds related to Rexahn Pharmaceuticals Inc. by keywords or tags. Find companies that have a similar focus to RNN. The keywords below have been associated to RNN by either user submission or electronic means.

Drugs Healthcare Common Stock Pharmaceutical Preparation Manufacturing (325412) Pharmaceutical Preparations (2834)